Jonathan Pachter

Company: Verastem

Job title: Chief Scientific Officer

Seminars:

The RAF/MEK Clamp VS-6766 for Treatment of KRAS & BRAF Mutant NSCLC 9:30 am

Exploring anti-tumor activity across multiple MAPK pathway alterations Ongoing VS-6766 combinations with FAK, KRAS G12C or mTOR inhibitors Revealing new combinations with EGFR inhibitorsRead more

day: Day Two